Celdara Medical today announced the appointment of Lynne Parshall, JD to the company’s board of directors.

“Lynne is an inspiring leader who knows exactly what it takes to transform world-changing concepts into valuable medicines. Her tenure as founding COO and Director at Ionis clearly demonstrates her thought leadership, delivering innovative modalities to underserved therapeutic areas. That Ionis now has five marketed drugs and 10 more in late-stage trials speaks to the operational excellence and culture she created. I’m very excited to work with her and learn from her.” said Dr. Jake Reder, CEO of Celdara Medical.

Celdara Medical today announced today announced the appointment of Dr. Wayne Frederick, MD, MBA as advisor to its board of directors.

Dr. Frederick is President Emeritus of Howard University and the Charles R. Drew Professor of Surgery at the Howard University College of Medicine. He is an active board member and advisor to multiple national and international organizations and is also a cancer surgeon and researcher at Howard University Hospital, where he continues to consult with patients and perform surgeries.

Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, today announced that it has enrolled its first patient in its R-2487 Phase 1 rheumatoid arthritis clinical trial.

"This is an important milestone for the company and patients suffering from rheumatoid arthritis" states Gary Fanger President and Chief Executive Officer of Rise Therapeutics. "This achievement reinforces our commitment to deliver innovative new medicines to the clinical community."

Celdara Medical and Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) today announced the signing of a Memorandum of Understanding (MOU) aimed at identifying and advancing promising new therapeutics in areas of high unmet medical need. Under the terms of this agreement, both organizations look to expand opportunities to provide financial support for the development of early-stage therapeutics by exchanging non-competitive information submitted in academic funding proposals.

Rockville, Maryland – Rise Therapeutics, a biotechnology company engaged in developing novel oral immunotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a rheumatoid arthritis Phase 1 clinical trial for its program candidate, R-2487. This is Rise Therapeutics’ second clinical program developed using synthetic biology and its proprietary oral biologics delivery platform.

The National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) has awarded Celdara Medical a Fast-Track Small Business Innovation Research (SBIR) grant to fund the development of engineered regulatory T cells (Tregs) therapy for Amyotrophic Lateral Sclerosis (ALS).